And this is the info which attracts the buyers: one of my last posts on the above mentioned thread:
"They do now say in the Annual Report that in the case of NIM (Norwood Immunology) listing (AIM board, London), there will be a placement. That could mean that the current smaller Aussie Holder will be cut out.
However, NAL's finances are already in good shape and that means that they could spin-off a smaller NIM stake than I referred to previously. If that is so, that could result in quite a handsome price for the floated-off stake, in turn increasing the value of NAL.
This would presumably occur after a big US Pharma has been chosen as a partner which in itself is a good catalyst for a NAL price rise and would really set the scene for that NIM listing.
Then, a Nasdaq listing of NAL is mentioned and that connection with NIM ought to be a powerful price stimulant for NAL as wel, I believe.
Immunology is the key word and I believe that NIM is a "goer" alright.
But it could be doubtful if the Aussie Investor gets a Nasdaq allocation. I need to inquire about that.
NAL is closely following NRT's procedure; the latter is slightly different but sofar has been very rewarding.
NRT and NAL are shrewd companies.
Gerry To readers: Circumstances may change. Please do your own research and you decide if and when to buy, hold or sell any stocks.
Voluntary Disclosure: Position Sentiment: None TOU violation
NAL Price at posting:
0.0¢ Sentiment: None Disclosure: Held
